Federico Rojo
Impact in
- Oncology top 0.1%
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Cancer Cells and Metastasis
- Cancer-related Molecular Pathways
- Peptidase Inhibition and Analysis
- Cancer Research top 0.5%
Papers in
- Oncology 137
- HER2/EGFR in Cancer Research 47
- Colorectal Cancer Treatments and Studies 22
- Cancer-related Molecular Pathways 16
-
- PI3K/AKT/mTOR signaling in cancer 23
- Co-authors
- José Baselga (23 shared papers)Joan Albanell (88 shared papers)Joaquı́n Arribas (11 shared papers)José Baselga (24 shared papers)Santiago Ramón y Cajal (14 shared papers)Ana Rovira (52 shared papers)Marta Guzmán (8 shared papers)Aňa Lluch (40 shared papers)
- Journals
- Journal of Clinical Oncology (50 papers)Clinical Cancer Research (15 papers)Cancers (12 papers)International Journal of Molecular Sciences (11 papers)Annals of Oncology (11 papers)
- Partner nations
- SpainUnited StatesGermany
In The Last Decade
Federico Rojo
263 papers receiving 13.4k citations
Federico Rojo's Hit Papers
Peers
Comparison fields: 5 of 136
- Oncology 6.5k
- Cancer Research 2.2k
- Molecular Biology 6.2k
- Pulmonary and Respiratory Medicine 2.6k
- Radiology, Nuclear Medicine and Imaging 1.5k
Countries citing papers authored by Federico Rojo
This map shows the geographic impact of Federico Rojo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Federico Rojo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Federico Rojo more than expected).
Fields of papers citing papers by Federico Rojo
This network shows the impact of papers produced by Federico Rojo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Federico Rojo. The network helps show where Federico Rojo may publish in the future.
Co-authors
The 25 scholars most cited alongside Federico Rojo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 269 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer Hit paper breakdown → | 2008 | 1149 |
| 2 | Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types Hit paper breakdown → | 2002 | 683 |
| 3 | Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer Hit paper breakdown → | 2007 | 667 |
| 4 | PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization Hit paper breakdown → | 2002 | 641 |
| 5 | Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Hit paper breakdown → | 2001 | 615 |
| 6 | A SNAIL1–SMAD3/4 transcriptional repressor complex promotes TGF-β mediated epithelial–mesenchymal transition Hit paper breakdown → | 2009 | 538 |
| 7 | Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial Hit paper breakdown → | 2002 | 498 |
| 8 | 2008 | 426 | |
| 9 | 2007 | 398 | |
| 10 | 2005 | 308 | |
| 11 | 2003 | 238 | |
| 12 | Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. | 2001 | 235 |
| 13 | 2004 | 232 | |
| 14 | 2007 | 228 | |
| 15 | 2003 | 221 | |
| 16 | 2002 | 217 | |
| 17 | ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. | 2003 | 213 |
| 18 | NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. | 2002 | 177 |
| 19 | 2007 | 166 | |
| 20 | 2006 | 162 |
About Federico Rojo
Federico Rojo is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Cancer Research and Pathology and Forensic Medicine, having authored 269 papers that have together received 13.6k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (47 papers), Lung Cancer Treatments and Mutations (33 papers), PI3K/AKT/mTOR signaling in cancer (23 papers), Colorectal Cancer Treatments and Studies (22 papers), Cancer Genomics and Diagnostics (18 papers), Breast Cancer Treatment Studies (17 papers), Cancer-related Molecular Pathways (16 papers) and MicroRNA in disease regulation (16 papers). The work is most often cited by research in Oncology (6.5k citations), Cancer Research (2.2k citations), Molecular Biology (6.2k citations), Pulmonary and Respiratory Medicine (2.6k citations) and Radiology, Nuclear Medicine and Imaging (1.5k citations). Federico Rojo has collaborated with scholars based in Spain, United States and Germany. Frequent co-authors include José Baselga, Joan Albanell, Joaquı́n Arribas, José Baselga, Santiago Ramón y Cajal, Ana Rovira, Marta Guzmán, Aňa Lluch, Jordi Codony‐Servat and Carlos L. Arteaga. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Cancers, International Journal of Molecular Sciences and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.